Acute portal hemodynamics and cytokine changes following selective transarterial chemoembolization in patients with cirrhosis and hepatocellular carcinoma

Medical Science Monitor

Volumn 9, Issue 9, 2003, Pages

  Spahr, Laurent ^a   Becker, Christoph ^a   Pugin, Jérôme ^a   Majno, Pietro E ^a   Hadengue, Antoine ^a  

^a UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Cirrhosis; Cytokine; Hepatocellular carcinoma; Portal flow velocity; TNF ; Transarterial chemoembolization

Indexed keywords

CYTOKINE; DOXORUBICIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; IODINATED POPPYSEED OIL; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; CHEMOEMBOLIZATION; CLINICAL ARTICLE; DOPPLER ECHOGRAPHY; FEMALE; HEMODYNAMICS; HUMAN; INFLAMMATION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER PERFUSION; MALE; PORTAL VEIN;

AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BLOOD FLOW VELOCITY; BODY TEMPERATURE; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; E-SELECTIN; FEMALE; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PORTAL PRESSURE; PORTAL VEIN; TUMOR NECROSIS FACTOR-ALPHA; ULTRASONOGRAPHY, DOPPLER, DUPLEX; VASCULAR CELL ADHESION MOLECULE-1;

EID: 0142058760     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Bruix J, Llovet JM, Castells A et al: Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology, 1998; 27: 1578-83
2. Llovet JM, Real MI, Montana X et al: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet, 2002; 359: 1734-9
3. Majno PE, Adam R, Bismuth H et al: Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg, 1997; 226: 688-701
4. Bianco S, Merkel C, Savastano S et al: Short-term effects of transcatheter arterial chemoembolisation on metabolic activity of the liver of cirrhotic patients with hepatocellular carcinoma. Gut, 1996; 39: 325-9
5. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire: Comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med, 1995; 332: 1256-61
6. Berger DH, Carrasco CH, Hohn DC et al: Hepatic artery chemoembolization or embolization for primary and metastatic liver tumors: post-treatment management and complications. J Surg Oncol, 1995; 60: 116-21
7. Sakamoto I, Aso N, Nagaoki K et al: Complications associated with transcatheter arterial embolization for hepatic tumors. Radiographics, 1998; 18: 605-19
8. Ohnishi K, Sato S, Tsunoda T et al: Portal venous hemodynamics in hepatocellular carcinoma. Effects of hepatic artery embolization. Gastroenterology, 1987; 93: 591-6
9. Taourel P, Dauzat M, Lafortune M et al: Hemodynamic changes after transcatheter arterial embolization of hepatocellular carcinoma. Radiology, 1994; 191: 189-92
10. Malkowski P, Michalowicz B, Pawlak J et al: Correlation between the hemodynamics of portal collateral circulation and the incidence of esophageal bleeding in patients with portal vein thrombosis - a preliminary report. Med Sci Monit, 2001; 7(suppl 1): 324-6
11. Okada K, Koda M, Murawaki Y et al: Changes in esophageal variceal pressure after transcatheter arterial embolization for hepatocellular carcinoma. Endoscopy, 2001; 33: 595-600
12. Lin DY, Hung CF, Chen PC et al: Gastrointestinal bleeding after hepatic transcatheter arterial embolization in patients with hepatocellular carcinoma. Gastrointest Endosc, 1996; 43: 132-7
13. Ikei S, Ogawa M, Beppu T et al: Changes in IL-6, IL-8, C-reactive protein and pancreatic secretory trypsin inhibitor after transcatheter arterial chemo-embolization therapy for hepatocellular carcinoma. Cytokine, 1992; 4: 581-4
14. Matsuda Y, Kawata S, Nagase T et al: Interleukin-6 in transcatheter arterial embolization for patients with hepatocellular carcinoma. Cancer, 1994; 73: 53-7
15. Itoh Y, Okanoue T, Ohnishi N et al: Hepatic damage induced by transcatheter arterial chemoembolization elevates serum concentrations of macrophage-colony stimulating factor. Liver, 1999; 19: 97-103
16. Adams DH: Lymphocyte-endothelial cell interactions in hepatic inflammation. Hepato-Gastroenterology, 1996; 43: 32-43
17. Volpes R, van den Oord JJ, Desmet VJ: Vascular adhesion molecules in acute and chronic liver inflammation. Hepatology, 1992; 15: 269-75
18. Jaeschke H: Cellular adhesion molecules: regulation and functional significance in the pathogenesis of liver diseases. Am J Physiol, 1997; 273: G602-G611
19. Vapaatalo H, Mervaala E: Clinically important factors influencing endothelial function. Med Sci Monit, 2001; 7(5): 1075-85
20. Bevilacqua MP, Pober JS, Mendrick DL et al: Identification of an inducible endothelial leukocyte adhesion molecule. Proc Natl Acad Sci, 1987; 84: 9238-42
21. Patriquin H, Lafortune M, Burns PN et al: Duplex Doppler examination in portal hypertension: technique and anatomy. AJR, 1987; 149: 71-6
22. Zoli M, Marchesini G, Cordiani MC et al: Echo-Doppler measurement of splanchnic blood flow in control and cirrhotic subjects. J Clin Ultrasound, 1986; 14: 429-35
23. Sabb/ C, Merkel C, Zoli M et al: Interobserver and interequipment variability of echo-Doppler examination of the portal vein: effect of cooperative training program. Hepatology, 1995; 21: 428-33
24. Sabb/ C, Weltin GG, Cicchetti DV et al: Observer variability in echo-Doppler measurements of portal blood flow in cirrhotic patients and normal volunteers. Gastroenterology, 1990; 98: 1603-11
25. Tilg H, Wilmer A, Vogel W et al: Serum levels of cytokines in chronic liver diseases. Gastroenterology, 1992; 103: 264-74
26. Iwao T, Toyonaga A, Oho K et al: Value of Doppler ultrasound parameters of portal vein and hepatic artery in the diagnosis of cirrhosis and portal hypertension. Am J Gastroenterol, 1997; 92: 1012-17
27. Moriyasu F, Ban N, Nishida O et al: Portal hemodynamics in patients with hepatocellular carcinoma. Radiology, 1986; 161: 707-11
28. Tsushima Y, Unno Y, Koizumi J et al: Hepatic perfusion changes after transcatheter arterial embolization (TAE) of hepatocellular carcinoma. Dig Dis Sci, 1998; 43: 317-22
29. Pugh RNH, Murray-Lyon M, Dawson JL et al: Transsection of oesophagus for bleeding oesophageal varices. Br J Surg, 1973; 60: 646-9
30. Jacobson ED, Pawlik WW: Adenosine regulation of mesenteric vasodilation. Gastroenterology, 1994; 107: 1168-80
31. Gülberg V, Haag K, Rössle M et al: Hepatic arterial buffer response in patients with advanced cirrhosis. Hepatology, 2002; 35: 630-4
32. Smyrniotis V, Kostopanagiotou G, Gamaletsos E et al: Hemodynamic interaction between portal vein and hepatic artery flow in small-for-size split liver transplantation. Transpl Int. 2002; 15: 355-60
33. Kawasaki T, Carmichael FJ, Saldivia V et al: Relationship between portal venous and hepatic arterial blood flows: spectrum of response. Am J Physiol, 1990; 259: C1010-1018
34. Lopez-Talavera JC, Merrill WW, Groszmann RJ: Tumor necrosis factor alpha: a major contributor to the hyperdynamic circulation in prehepatic portal-hypertensive rats. Gastroenterology, 1995; 108: 761-7
35. Munoz J, Albillos A, Perez-Paramo M et al: Factors mediating the hemodynamic effects of tumor necrosis factor-a in portal hypertensive rats. Am J Physiol, 1999; 276: G687-93
36. Adams DH, Burra P, Hubscher SG et al: Endothelial activation and circulating vascular adhesion molecules in alcoholic liver disease. Hepatology, 1994; 19: 588-94
37. Paquet KJ: Causes and pathomechanisms of oesophageal varices development. Med Sci Monit, 2000; 6(5): 915-28